Get started
Author

Douglas P. Wilson

Observed names: D. Wilson, Douglas Wilson
ORCID: 0009-0003-8468-0284
Observed ORCID: 0009-0003-8468-0284
OpenAlex ID: A5102996769
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
2018 · Vivek Subbiah, Justin F. Gainor, et al. · Cancer Discovery · 417
Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer
2022 · Meredith S. Eno, Jason D. Brubaker, et al. · Journal of Medicinal Chemistry · 202
PDF
A Highly Facile and Efficient One-Step Synthesis of N6-Adenosine and N6-2‘-Deoxyadenosine Derivatives
2005 · Zhao-Kui Wan, Eva Binnun, et al. · Organic Letters · 70
1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
2020 · S.S. Schalm, T. Dineen, et al. · Annals of Oncology · 54
PDF
An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva
2024 · Alison J. Davis, Natasja Brooijmans, et al. · Science Translational Medicine · 27
Abstract 2306: BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer models
2022 · Victoria Brown, Phil Ramsden, et al. · Cancer Research · 15
384P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
2020 · S.S. Schalm, T. Dineen, et al. · Annals of Oncology · 13
PDF
Abstract P6-10-07: CDK2 inhibition with BLU-222 in combination with ribociclib demonstrates robust antitumor activity in pre-clinical models of CDK4/6 inhibitor-naïve and -resistant HR+/HER2- breast cancer
2023 · Victoria Brown, Nealia House, et al. · Cancer Research · 11
Abstract B151: BLU-667 is a potent and highly selective RET inhibitor being developed for RET-driven cancers
2018 · Rami Rahal, Michelle Maynard, et al. · Molecular Cancer Therapeutics · 7
Abstract B01: BLU-667: A highly selective RET inhibitor to target RET-driven NSCLC
2018 · Rami Rahal, Michelle Maynard, et al. · Clinical Cancer Research
Works count: 10
Citation count: 816
H-index: 8
I10-index: 8
Year
Topic
Type